ASPIVIX partners with women's health clinic Tia to introduce its cervical device

Women in 9 Tia clinics in the US will be able to receive care with the soft suction cervical device

Image: ASPIVIX

Gynaecological solutions company ASPIVIX is partnering with women’s health clinic Tia to offer women its pain-reducing solution for IUD insertions.

For the first time in the US, women in 9 Tia clinics in LA, New York, San Francisco and Scottsdale will be able to receive care with the pioneering ASPIVIX cervical device ‘Carevix.’

The soft-suction cervical device is a modern and gentler alternative to the tenaculum, designed as a more comfortable experience for both patients and for healthcare providers. By stabilising the cervix using a soft-suction method, it is used as a less painful alternative to the tenaculum in transcervical procedures in gynaecology, oncology and fertility, including IUD/ coil insertions.

This partnership marks ASPIVIX’s further expansion into the US market, following FDA-approval of Carevix in 2023 and positive clinical data presented at ACOG 2024.

Devon Klauck, WHNP, Senior Director, Clinical Product at Tia, said:

"At Tia, we prioritise listening to women and addressing their needs. We know that IUD insertions can be a painful experience, and we’ve heard women’s frustrations about their pain being dismissed or minimised.

“That’s why we’re excited to partner with ASPIVIX as part of their Ambassador Program to offer Carevix, a breakthrough device that reduces pain during IUD insertions. By integrating Carevix alongside our existing pain management options, we are committed to providing a more comfortable and compassionate experience for our patients."

Doctors urged to prioritise pain management

ASPIVIX is well-placed for commercialisation in the US, particularly after the Centers for Disease Control and Prevention (CDC) recently updated its guidelines aimed at making IUD insertion less painful. It urged doctors to inform women about the potential pain and counsel them about their pain management options.

Ikram Guerd, General Manager US of ASPIVIX, said:

"With the CDC urging physicians to better manage pain during IUD procedures, our partnership with Tia represents a victory for women advocating for better care. It’s an important step for ASPIVIX as we continue to align our patient-centric solution.

"Tia joins University hospitals already using Carevix, IU Health School of Medicine and Columbia University, allowing ASPIVIX to expand our reach in the US market with the right partners advancing women's health and making significant advancements in gynecological care."

Over 700 patients globally have now experienced enhanced care with Carevix, with over 90% reporting satisfaction for IUD and other transcervical procedures (hysteroscopy, endocervical biopsies...).

Earlier this month Carevix was also introduced to its first UK hospital, as ASPIVIX announced approval from the Medicines & Healthcare products Regulatory Agency (MHRA) which allows for its use in the UK.